Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Income towards Parent Company (2019 - 2026)

Relay Therapeutics has reported Income towards Parent Company over the past 6 years, most recently at -$54.9 million for Q4 2025.

  • Quarterly Income towards Parent Company rose 27.74% to -$54.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$275.7 million through Dec 2025, up 18.36% year-over-year, with the annual reading at -$275.7 million for FY2025, 18.36% up from the prior year.
  • Income towards Parent Company was -$54.9 million for Q4 2025 at Relay Therapeutics, up from -$74.0 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at -$42.2 million in Q1 2021 and troughed at -$193.4 million in Q2 2021.
  • The 5-year median for Income towards Parent Company is -$76.4 million (2022), against an average of -$80.5 million.
  • Year-over-year, Income towards Parent Company crashed 623.69% in 2021 and then surged 60.29% in 2022.
  • A 5-year view of Income towards Parent Company shows it stood at -$67.5 million in 2021, then decreased by 0.03% to -$67.5 million in 2022, then fell by 23.74% to -$83.5 million in 2023, then rose by 8.97% to -$76.0 million in 2024, then increased by 27.74% to -$54.9 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Income towards Parent Company are -$54.9 million (Q4 2025), -$74.0 million (Q3 2025), and -$69.7 million (Q2 2025).